Zoetis Inc. (NYSE:ZTS – Get Rating)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $155.91 and last traded at $156.00, with a volume of 9032 shares trading hands. The stock had previously closed at $161.49.
Several brokerages have commented on ZTS. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Citigroup dropped their price target on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 9th. Finally, The Goldman Sachs Group dropped their price target on shares of Zoetis from $237.00 to $208.00 and set a “buy” rating on the stock in a research note on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $230.43.
The stock has a market capitalization of $73.50 billion, a P/E ratio of 37.04, a PEG ratio of 2.71 and a beta of 0.77. The company has a debt-to-equity ratio of 1.12, a current ratio of 2.25 and a quick ratio of 1.58. The stock’s fifty day moving average is $174.87 and its two-hundred day moving average is $196.06.
Zoetis (NYSE:ZTS – Get Rating) last issued its earnings results on Thursday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.10. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.98 billion. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share. Analysts expect that Zoetis Inc. will post 5.06 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Thursday, July 21st will be issued a dividend of $0.325 per share. This represents a $1.30 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date is Wednesday, July 20th. Zoetis’s payout ratio is 29.82%.
In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction that occurred on Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total value of $387,806.32. Following the completion of the sale, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,239,025.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Roman Trawicki sold 6,000 shares of the stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $188.15, for a total transaction of $1,128,900.00. The disclosure for this sale can be found here. Company insiders own 0.12% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. J.W. Cole Advisors Inc. raised its holdings in shares of Zoetis by 5.1% during the 1st quarter. J.W. Cole Advisors Inc. now owns 2,967 shares of the company’s stock valued at $560,000 after purchasing an additional 143 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Zoetis by 0.6% during the 1st quarter. Bank of America Corp DE now owns 12,775,847 shares of the company’s stock valued at $2,409,397,000 after purchasing an additional 78,088 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Zoetis by 9.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 136,215 shares of the company’s stock valued at $25,689,000 after purchasing an additional 12,232 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Zoetis during the 1st quarter valued at $446,000. Finally, Martin Currie Ltd. raised its holdings in shares of Zoetis by 2.5% during the 1st quarter. Martin Currie Ltd. now owns 107,471 shares of the company’s stock valued at $20,268,000 after purchasing an additional 2,571 shares in the last quarter. Institutional investors own 90.73% of the company’s stock.
About Zoetis (NYSE:ZTS)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading
Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
